Immunotherapy in Renal Cell Carcinoma: The Future Is Now.
PD-1
PD-L1
biomarkers
emerging drugs
immune checkpoint inhibitors
immunotherapy
ongoing trials
renal cell carcinoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
05 Apr 2020
05 Apr 2020
Historique:
received:
02
03
2020
revised:
30
03
2020
accepted:
02
04
2020
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
16
12
2020
Statut:
epublish
Résumé
Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare with a high rate of resistance. New strategies are emerging to improve the efficacy and the emerging drugs are under evaluation in ongoing trials. With the different treatment options, there is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients. Owing to the limitations of programmed death-ligand 1 (PD-L1), the most studied immunohistochemistry biomarkers, and of the tumor mutational burden, the identification of more reliable markers is an unmet need. New technologies could help in this purpose.
Identifiants
pubmed: 32260578
pii: ijms21072532
doi: 10.3390/ijms21072532
pmc: PMC7177761
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Am J Surg Pathol. 2014 May;38(5):627-37
pubmed: 24441663
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Int J Mol Sci. 2019 Apr 04;20(7):
pubmed: 30987368
Diagn Pathol. 2015 Oct 15;10:189
pubmed: 26470780
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2016 Dec 8;375(23):2246-2254
pubmed: 27718781
Cell. 2012 Jul 6;150(1):12-27
pubmed: 22770212
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Clin Cancer Res. 2016 Feb 15;22(4):813-20
pubmed: 26880610
Front Oncol. 2019 Apr 05;9:228
pubmed: 31024837
Cancer Res. 2017 Mar 1;77(5):1212-1226
pubmed: 28087600
Clin Cancer Res. 2007 Mar 15;13(6):1757-61
pubmed: 17363529
World J Biol Chem. 2015 Nov 26;6(4):281-9
pubmed: 26629311
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Nat Rev Immunol. 2006 Aug;6(8):613-8
pubmed: 16868552
Jpn J Clin Oncol. 2017 Jul 1;47(7):639-646
pubmed: 28419248
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
J Immunother. 2020 Jan;43(1):16-28
pubmed: 31574023
Eur Urol. 2016 Aug;70(2):348-57
pubmed: 26895810
Anticancer Res. 2011 Dec;31(12):4219-21
pubmed: 22199284
Cancer Sci. 2018 May;109(5):1583-1591
pubmed: 29498788
Cancer Immunol Res. 2016 Oct;4(10):820-822
pubmed: 27538576
J Clin Oncol. 1995 Mar;13(3):688-96
pubmed: 7884429
J Immunother Cancer. 2018 Jan 29;6(1):9
pubmed: 29378660
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
J Immunother Cancer. 2018 Jun 18;6(1):57
pubmed: 29914571
Eur Urol. 2020 Apr;77(4):420-433
pubmed: 31563503
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Eur Urol. 2015 Apr;67(4):740-9
pubmed: 24882670
Clin Cancer Res. 2016 Nov 15;22(22):5461-5471
pubmed: 27169994
Am J Pathol. 2009 Dec;175(6):2657-67
pubmed: 19875502
J Immunol. 2008 Aug 1;181(3):1969-77
pubmed: 18641334
Sci Rep. 2016 Aug 03;6:30988
pubmed: 27484008
J Exp Med. 2011 Mar 14;208(3):577-92
pubmed: 21383057
Lancet Oncol. 2020 Jan;21(1):95-104
pubmed: 31810797
Mod Pathol. 2019 Sep;32(9):1344-1358
pubmed: 30996253
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
Expert Opin Pharmacother. 2014 Feb;15(2):283-97
pubmed: 24328549
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Lancet Oncol. 2018 Sep;19(9):1180-1191
pubmed: 30120041
Cancers (Basel). 2020 Jan 17;12(1):
pubmed: 31963500
Cancer Discov. 2019 Apr;9(4):510-525
pubmed: 30622105
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Cancer Immunol Res. 2015 Dec;3(12):1303-7
pubmed: 26307625
Eur J Cancer. 2016 Jan;52:50-66
pubmed: 26645943
Cell. 2018 Sep 6;174(6):1586-1598.e12
pubmed: 30100188
Mol Cell. 2019 Jul 11;75(1):7-12
pubmed: 31299208
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Future Sci OA. 2017 Mar 27;3(2):FSO190
pubmed: 28670477
Clin Cancer Res. 2015 Mar 15;21(6):1329-39
pubmed: 25583177
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s
pubmed: 17255298
Eur Urol. 2011 Oct;60(4):615-21
pubmed: 21741761
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Cancer Immunol Immunother. 2009 Sep;58(9):1517-26
pubmed: 19259667
Clin Cancer Res. 2013 Sep 1;19(17):4673-84
pubmed: 23817689
Oncotarget. 2016 Sep 13;7(37):59877-59891
pubmed: 27494883
Eur Urol. 2015 Apr;67(4):729-37
pubmed: 24836153
Clin Genitourin Cancer. 2017 Dec;15(6):e987-e994
pubmed: 28558987
Pharmacol Ther. 2019 Mar;195:162-171
pubmed: 30439456
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
Immunity. 2016 May 17;44(5):989-1004
pubmed: 27192565
Trends Pharmacol Sci. 2018 Mar;39(3):307-325
pubmed: 29254698
Hum Pathol. 2012 Nov;43(11):1982-90
pubmed: 22626276
Mol Clin Oncol. 2019 Feb;10(2):244-248
pubmed: 30680202
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428
pubmed: 28213366
Ann Oncol. 2014 Nov;25(11):2178-84
pubmed: 25193987
Lancet Oncol. 2013 Feb;14(2):141-8
pubmed: 23312463
Cancer Res. 2014 Apr 1;74(7):1933-44
pubmed: 24691994
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
Clin Cancer Res. 2019 Jul 1;25(13):3934-3945
pubmed: 30940657
Breast Cancer Res. 2014 Jul 25;16(4):410
pubmed: 25060643
Cancer Manag Res. 2019 Jul 25;11:7021-7030
pubmed: 31440091
Cancer Res. 2006 Apr 1;66(7):3381-5
pubmed: 16585157
Genome Biol. 2016 Apr 29;17:80
pubmed: 27139883
J Immunol Res. 2018 Dec 19;2018:4325874
pubmed: 30662919
Semin Diagn Pathol. 2015 Mar;32(2):103-13
pubmed: 25758327
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
PLoS One. 2012;7(2):e30676
pubmed: 22363469
J Exp Med. 2010 Sep 27;207(10):2187-94
pubmed: 20819927
Immunology. 2009 Sep;128(1 Suppl):e728-37
pubmed: 19740334
J Clin Oncol. 2002 Jan 1;20(1):289-96
pubmed: 11773181
Cancer. 2013 Apr 15;119(8):1547-54
pubmed: 23335244
J Natl Compr Canc Netw. 2019 Nov 1;17(11):1278-1285
pubmed: 31693980
Adv Anat Pathol. 2014 May;21(3):174-80
pubmed: 24713987
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Br J Cancer. 2018 Oct;119(7):840-846
pubmed: 30293996
Nat Rev Cancer. 2015 Jan;15(1):55-64
pubmed: 25533676
Eur Urol. 2019 Aug;76(2):151-156
pubmed: 31151678
Int J Mol Sci. 2017 Jul 01;18(7):
pubmed: 28671573
Eur Urol. 2019 Jan;75(1):100-110
pubmed: 30327274